Search Results
Jul 31, 2026, 06:03 ET ECARX-Backed Chip Maker SiEngine Secures US$200M Equity Financing to Accelerate Vertical Silicon-to-Software SDV Innovation
strong cost-performance advantages for intelligent mobility platforms.This US$200 million equity injection will fuel SiEngine's next-phase R&D, production capacity expansion, globalization and international customer growth, further strengthening the unique ECARX vertical silicon-to-software
More news about: ECARX Holdings Inc.
Jul 31, 2026, 04:03 ET IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand
integrated R&D platform that enables innovation across both small molecules and emerging modalities, including ADCs and degraders. Additionally, we have forged partnerships with leading global biotech and China pharmaceutical companies to date, as validation of our pipeline and R&D platform.About
More news about: IMPACT Therapeutics
Jul 31, 2026, 03:48 ET IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand
integrated R&D platform that enables innovation across both small molecules and emerging modalities, including ADCs and degraders. Additionally, we have forged partnerships with leading global biotech and China pharmaceutical companies to date, as validation of our pipeline and R&D platform.About
More news about: IMPACT Therapeutics
Jul 31, 2026, 02:15 ET CellOrigin Unveils Two Novel Solid-Tumor Cell Therapy Candidates at ASCO 2026, Partners with Walvax for In Vivo CAR Clinical Trial
industrial capabilities, the two companies aim to accelerate the clinical translation of novel therapies for solid tumors.Through sustained R&D investment, CellOrigin has established a comprehensive in vivo CAR technology platform addressing solid tumors, autoimmune diseases and organ fibrosis.
More news about: CellOrigin
Jul 31, 2026, 02:04 ET FIRST AMGEN SCHOLARS PROGRAM IN INDIA LAUNCHES AT IIIT HYDERABAD
ecosystem.""We are delighted to serve as the host institution for the first Amgen Scholars Program in India," said Deva Priyakumar, Professor & Dean (R&D), IIIT Hyderabad. "The program aligns well with our research-led approach to education and provides undergraduate students with an exceptional opportunity
More news about: Amgen
Jul 31, 2026, 00:56 ET 아부다비 문화관광부, 2026년 12월 11일 구겐하임 아부다비 개관 발표
abudhabiculture.ae솔로몬 R. 구겐하임 재단 소개솔로몬 R. 구겐하임 재단은 1937년 설립되었으며 전시, 교육 프로그램, 연구 활동, 출판물을 통해 근현대 미술에 대한 이해와 감상을 증진하는 데 전념하고 있다. 혁신에 대한 확고한 의지를 바탕으로, 솔로몬 R. 구겐하임 재단은 근현대 미술을 수집, 보존, 해석하며, 역동적인 큐레이터십과 교육 이니셔티브, 협력을 통해 문화를 넘나드는 사상을 탐구한다.
More news about: Department of Culture and Tourism - Abu Dhabi
Jul 30, 2026, 21:55 ET MSFT Deadline: MSFT Investors Have Opportunity to Lead Microsoft Corporation Securities Fraud Lawsuit
in order to improve the competitive positioning of its critical Copilot family of products and increase its AI-related research and development ("R&D"); and (4) as a result, Microsoft had failed to convert a significant percentage of its commercial Microsoft 365 users to paid Copilot subscriptions
More news about: THE ROSEN LAW FIRM, P. A.
Jul 30, 2026, 21:01 ET Kaigene Enters into Exclusive Licensing Agreement with Taisho Pharmaceutical for Next-Generation Autoimmune Asset KG006 in Japan
antibody Nanozora®. Taisho continues to expand its biopharmaceutical footprint through strategic pipelines, licensing opportunities, and ongoing R&D investments. To learn more, please visit www.taisho.co.jp.Media Contact:
More news about: Kaigene
Jul 30, 2026, 19:50 ET U.S. Renal Care Drives Innovation in Dialysis with Increased Availability of Medium Cut-Off Dialyzers to Support Expanded Hemodialysis
comparison with other high-flux dialyzsers in conventional hemodialysis and online hemodiafiltration.6 Kandi M, Brignardello-Petersen R, Couban R, Wu C, Nesrallah G. Clinical outcomes with medium cut-off versus high-flux hemodialysis membranes: A systematic review and meta-analysis. Can
More news about: U.S. Renal Care
Jul 30, 2026, 16:40 ET New Hampshire's First Skyscraper, Reborn: Rendezvous on Elm offers 27 Luxury Residences, Receives Recognition
the building itself. Sound control exceeds three separate industry standards: sound-transmission class (STC), noise-reduction coefficient (NRC), and R-value insulation, through steel framing paired with resilient sound-isolation clips.Meanwhile, a fresh-air makeup system in every home replaces
More news about: Rendezvous on Elm
Jul 30, 2026, 16:30 ET Corteva Delivers Strong 1H 2026, Raises FY 2026 Outlook, On-Track for October 1 Separation
quarter of 2025. Price/mix, reductions in net royalty expense, and ongoing cost and productivity actions more than offset lower volumes and increased R&D and functional cost. Segment operating EBITDA margin improved by over 230 basis points versus the prior-year period.
More news about: Corteva Agriscience
Jul 30, 2026, 16:20 ET Huntsman Announces Third Quarter 2026 Common Dividend
are sold worldwide to manufacturers serving a broad and diverse range of consumer and industrial end markets. We operate more than 55 manufacturing, R&D and operations facilities in approximately 25 countries and employ approximately 6,000 associates within our continuing operations. For more information
More news about: Huntsman Corporation
Jul 30, 2026, 16:15 ET Huntsman Announces Second Quarter 2026 Earnings
net loss attributable to Huntsman of $6 million, adjusted net income attributable to Huntsman of nil and adjusted EBITDA of $120 million. Peter R. Huntsman, Chairman, President, and CEO, commented:"We delivered a solid quarter, supported by higher volumes across all three segments and
More news about: Huntsman Corporation
Jul 30, 2026, 16:11 ET /C O R R E C T I O N -- Mitsubishi Motors North America, Inc./
More news about: Mitsubishi Motors North America, Inc.
Jul 30, 2026, 16:05 ET Penumbra, Inc. Reports Second Quarter 2026 Financial Results
the second quarter of 2025.Total operating expenses of $223.9 million in the second quarter of 2026, comprised of R&D of $25.4 million and SG&A of $198.5 million, which includes $6.9 million of acquisition-related expenses associated with the pending acquisition
More news about: Penumbra, Inc.
Jul 30, 2026, 16:05 ET Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026
accomplish our desired operational goals; (xiii) our ability to realize the anticipated benefits from prior or future actions to streamline and improve our R&D processes, reduce our operating expenses and maximize our revenue growth; (xiv) our ability to further develop and commercialize our instruments, consumables,
More news about: Illumina, Inc.
Jul 30, 2026, 16:01 ET PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
revenue.Based on US GAAP (Generally Accepted Accounting Principles), GAAP R&D expenses were $99.2 million for the second quarter of 2026, compared to $113.0 million for the second quarter of 2025.Non-GAAP R&D expenses were $88.6 million for the second quarter of 2026, excluding $10.5
More news about: PTC Therapeutics, Inc.
Jul 30, 2026, 16:01 ET Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
candidates. Development milestones are included in R&D guidance once achieved or deemed probable to achieve.Non-GAAP guidance has been adjusted to exclude estimated non-cash stock-based compensation expense of approximately $115 million in R&D and $170 million in SG&A, including approximately
More news about: Neurocrine Biosciences, Inc.
Jul 30, 2026, 14:12 ET Securities Fraud Investigation Into Pentair plc (PNR) Continues - Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz continues its investigation of Pentair plc ("Pentair" or the "Company") (NYSE:
More news about: The Law Offices of Frank R. Cruz, Los Angeles
Jul 30, 2026, 14:01 ET Securities Fraud Investigation Into GE HealthCare Technologies Inc. (GEHC) Continues - Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz continues its investigation of GE HealthCare Technologies Inc. ("GE HealthCare" or the "Company") (NASDAQ:
More news about: The Law Offices of Frank R. Cruz, Los Angeles
Jul 30, 2026, 13:54 ET Friends of PAHO Leads Call from Health, Security, and Business Leaders for Continued U.S. Leadership in the Pan American Health Organization
Ronald R. Blanck, 39th Army Surgeon General; Seth Berkley, Former CEO, Gavi, the Vaccine Alliance; Stefano Bertuzzi, CEO, American Society for Microbiology; Steve Morrison, Senior Vice President, Center for Strategic and International Studies; Rear Adm. (Ret) R. Tim
More news about: Friends of PAHO
Jul 30, 2026, 13:46 ET Embecta Corp. (EMBC) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
The Law Offices of Frank R. Cruz announces that investors with losses related to Embecta Corp. (EMBC) have opportunity to lead the securities fraud class action
More news about: The Law Offices of Frank R. Cruz, Los Angeles
Jul 30, 2026, 13:07 ET POSITIVE STELLUNGNAHME DES CHMP UNTERSTÜTZT BREITERE ANWENDUNG VON AMGENS REPATHA® VOR ERSTEM HERZINFARKT ODER SCHLAGANFALL
10.4330/wjc.v18.i2.114960. PMID: 41694036; PMCID: PMC12897005.Data on File. Amgen, 2025.Data on File. Amgen, 2025.Ndumele, C. E., & Blumenthal, R. S. (2025). VESALIUS and the Anatomy of High-Risk Prevention. New England Journal of Medicine.
More news about: Amgen